Medtronic on Tuesday announced one of its insulin pump systems, the Minimed 770G, has received approval from the U.S. Food and Drug Administration. The medical device company is headquartered in Dublin, but its diabetes division operates out of Northridge. The company’s latest insulin pump is available to children with Type 1 diabetes, and offers users the technology to see pump data in real time. The system can also send data to clinicians and educators if needed. “We’re thrilled to be launching this new system as we understand how important these data-sharing features are, particularly right now — with many individuals and families opting to see their doctors virtually via telehealth visits,” Sean Salmon, vice president of Medtronic Diabetes Group, said in a statement. Medtronic will begin taking orders for the MiniMed 770G in the United States this week, the company said. Shares of Medtronic (MDT) closed Tuesday up 5 cents, or a fraction of a percent, to $107.52 on the New York Stock Exchange.
